How should hospital procurement teams hedge shortage risk in the Opioids Market?

Dual-source every Schedule II injectable and write guaranteed fill-rate clauses with penalty terms into primary contracts. Pay the 6–9% reliability premium rather than relying on spot purchasing during allocation events [5]. Read More

What due-diligence red flags matter most for investors evaluating Opioids Market assets?

Check whether litigation liabilities were discharged or merely deferred, and confirm DEA quota allocations transfer with the asset. Unassigned quota can strand an otherwise sound manufacturing acquisition [12]. Read More

Do abuse-deterrent formulations actually earn their price premium?

Only where formulary policy mandates them. Fourteen state Medicaid programs enforce preference, making the premium collectible; in open tenders, generics win on price [2]. Read More

How does quota allocation constrain contract manufacturing decisions in the Opioids Market?

Quota attaches to the registrant, not the facility, so CMOs cannot absorb overflow from a constrained client. Capacity planning must therefore begin with allocation negotiations, not demand forecasts [1]. Read More

Which liabilities remain with generic manufacturers after the major settlements?

State and tribal claims are largely resolved, but third-party payer and personal-injury suits continue in several jurisdictions. Indemnity carve-outs in asset sales deserve close reading [12]. Read More

What role do veterinary and hospice channels play commercially?

Both are small, fragmented, and margin-accretive because they require small-batch flexibility that scale generics avoid. Neither faces the retail prescribing scrutiny that suppresses outpatient volumes. Read More

How do formulary committees weigh non-opioid substitutes against incumbents?

Committees compare total episode cost, including readmission and dependence risk, not acquisition price. Suzetrigine clears review despite costing far more per dose, where surgical protocols document downstream savings [6]. Read More

Opioids Market (2026 - 2035)

Opioids Market Research Report: Size, Share, Trend Analysis By Drug Type (Natural Opioids, Semi-synthetic Opioids, Fully Synthetic Opioids, Opioid Derivatives), By Route of Administration (Oral, Injectable, Transdermal, Rectal, Nasal), By Therapeutic Application (Pain Management, Cough Suppression, Diarrhea Treatment, Anesthesia), By Patient Population (Chronic Pain Patients, Postoperative Pain Patients, Cancer Patients, Palliative Care Patients) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2026-2035

CAGR

3.95%

2025 Market Size

USD 26.58 Billion

2035 Market Size

USD 39.15 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/6157-CR | Pages: 200 | Author: Vikita Thakur, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2024) |
2. 3.2 Base Year Estimate (2025) |
3. 3.3 Forecast Market Size (2026–2035) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Medication-Assisted Treatment Reimbursement |
2. 4.2 Surgical Volume Recovery |
3. 4.3 Palliative Care Expansion in Emerging Economies |
4. 4.4 Abuse-Deterrent Formulation Economics
5 Restraints Impact Analysis |
1. 5.1 Quota Compression |
2. 5.2 Prescribing Surveillance |
3. 5.3 Substitute Chemistry
6 Opportunities |
1. 6.1 Long-Acting Injectable Dependence Therapy |
2. 6.2 Emerging-Market Access Build-Out |
3. 6.3 Stewardship Analytics as a Revenue Line |
4. 6.4 Hospital Supply-Chain Resilience Contracts |
5. 6.5 Veterinary and Specialty Palliative Channels
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Algorithmic Dosing and Stewardship |
2. 8.2 Supply-Chain Onshoring |
3. 8.3 Value-Based Contracting |
4. 8.4 Portfolio Diversification
9 Market Segmentation Analysis |
1. 9.1 By Product Type | |
  1. 9.1.1 Codeine | |
  2. 9.1.2 Fentanyl | |
  3. 9.1.3 Meperidine | |
  4. 9.1.4 Oxycodone | |
  5. 9.1.5 Hydrocodone | |
  6. 9.1.6 Morphine | |
  7. 9.1.7 Methadone | |
  8. 9.1.8 Tramadol | |
  9. 9.1.9 Buprenorphine | |
  10. 9.1.10 Others |
2. 9.2 By Receptor Binding | |
  1. 9.2.1 Strong Agonist | |
  2. 9.2.2 Mild to Moderate Agonist | |
  3. 9.2.3 Partial Agonist | |
  4. 9.2.4 Mixed Agonist-Antagonist and Others |
3. 9.3 By Route of Administration | |
  1. 9.3.1 Oral | |
  2. 9.3.2 Parenteral / IV | |
  3. 9.3.3 Transdermal | |
  4. 9.3.4 Others |
4. 9.4 By Application | |
  1. 9.4.1 Pain Management | |
  2. 9.4.2 Cold and Cough | |
  3. 9.4.3 Opioid-Dependence Therapy | |
  4. 9.4.4 Anesthesia Adjunct | |
  5. 9.4.5 Others |
5. 9.5 By Distribution Channel | |
  1. 9.5.1 Hospital | |
  2. 9.5.2 Retail Pharmacy | |
  3. 9.5.3 Specialty Clinic | |
  4. 9.5.4 Online Pharmacy
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles
11 Recent News & Developments
12 Report Scope & Methodology
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES
16 LIST OF FIGURES

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Product Type	Codeine, Fentanyl, Meperidine, Oxycodone, Hydrocodone, Morphine, Methadone, Tramadol, Buprenorphine, Others	Oxycodone	Buprenorphine
By Receptor Binding	Strong Agonist, Mild to Moderate Agonist, Partial Agonist, Mixed Agonist-Antagonist, and Others	Strong Agonist	Partial Agonist
By Route of Administration	Oral, Parenteral / IV, Transdermal, Others	Parenteral / IV	Transdermal
By Application	Pain Management, Cold and Cough, Opioid-Dependence Therapy, Anesthesia Adjunct, Others	Pain Management	Opioid-Dependence Therapy
By Distribution Channel	Hospital, Retail Pharmacy, Specialty Clinic, Online Pharmacy	Hospital	Online Pharmacy
By Geography	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Product Type

Sub-Segment	Key Trend
Codeine	Antitussive reformulation and pediatric restrictions reshape volume
Fentanyl	Transdermal oncology use offsets injectable quota limits
Meperidine	Steady clinical retirement from perioperative protocols
Oxycodone	Branded abuse-deterrent versions defend price against volume decline
Hydrocodone	Combination-product scheduling continues to compress prescribing
Morphine	Remains the WHO essential-medicine reference for severe pain
Methadone	Take-home flexibility rules restructure clinic economics
Tramadol	Emerging-market step-two analgesia growth with rising scheduling scrutiny
Buprenorphine	Depot formulations shift dependence therapy to monthly dosing
Others	Specialty breakthrough-pain and combination products

Molecule-level performance now diverges sharply by regulatory treatment rather than clinical merit. Quota-constrained agonists trade volume for price, while dependence-therapy molecules expand on public funding.

By Receptor Binding

Sub-Segment	Key Trend
Strong Agonist	Anchored in hospital, oncology, and trauma settings
Mild to Moderate Agonist	Outpatient prescribing declines under monitoring programs
Partial Agonist	Ceiling-effect safety profile drives treatment adoption
Mixed Agonist-Antagonist and Others	Niche reversal and specialty analgesia applications

Pharmacological classification increasingly predicts reimbursement outcomes. Payers reward partial agonists for their reduced respiratory-depression risk, accelerating formulary migration away from full agonists in maintenance settings.

By Route of Administration

Sub-Segment	Key Trend
Oral	Tablet volumes fall as prescription quantities shrink
Parenteral / IV	Shortage-driven contracting favors resilient suppliers
Transdermal	Continuous release wins in hospice and dysphagia populations
Others	Nasal and buccal formats serve breakthrough cancer pain

Delivery format determines exposure to prescribing surveillance. Hospital-administered routes remain insulated, while outpatient oral products absorb most of the policy-driven contraction.

By Application

Sub-Segment	Key Trend
Pain Management	Multimodal protocols reduce per-case exposure without cutting case counts
Cold and Cough	Regulatory restrictions narrow the codeine antitussive base
Opioid-Dependence Therapy	Public funding and depot dosing expand treated populations
Anesthesia Adjunct	Procedural sedation demand tracks ambulatory surgery growth
Others	Dyspnea, diarrhea, and specialty palliative indications

Application mix is the clearest structural shift underway. Therapy for dependence is converting from a public-health cost centre into a commercially attractive franchise with outcome-linked contracting.

By Distribution Channel

Sub-Segment	Key Trend
Hospital	Group purchasing consolidation raises supplier qualification bars
Retail Pharmacy	Dispensing caps and query mandates suppress script volumes
Specialty Clinic	Opioid treatment programs expand under accreditation reform
Online Pharmacy	E-prescribing rules unlock compliant mail-order growth

Channel economics now diverge more than product economics. Hospital contracting rewards reliability, retail rewards nothing at all, and online dispensing grows from a small base under newly permissive telehealth rules.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”